The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

HEC 68498

HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.

DRUG

Placebo

Placebo

Trial Locations (1)

32117

Covance Clinical Research Unit, Inc., Daytona Beach

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY